Wednesday, September 22, 2021
Home Tags PP Defence Therapeutics

PP Defence Therapeutics Related News

new COVID vaccine

Defence Therapeutics’ new COVID vaccine achieves successful testing

Biotechnology experts Defence Therapeutics have sensationally announced that their new COVID vaccine has demonstrated effectiveness in a non-rodent model. The new COVID vaccine – called...
HPV vaccine

Defence Therapeutics unveil novel HPV vaccine development programme

Industry-leading biotechnology company Defence Therapeutics has revealed that it will be establishing a high priority programme to develop a new HPV vaccine for cervical...
Accum-vaccine

Versatile Accum technology for various immune-oncology needs

Defence Therapeutics explains how its Accum™ technology can enhance the delivery of tumour and infectious disease-specific therapeutics. The principal technology developed by Defence Therapeutics (DT)...
drug-delivery-Defence-Therapeutics

Defence Therapeutics selects new variants to optimise drug delivery

Following a thorough evaluation process, Defence Therapeutics has selected the eight most successful variants of its Accum™ drug delivery technology. Biotechnology company Defence Therapeutics continually works...
Defence Therapeutics

Defence Therapeutics: At the forefront of biotech innovation

In this article, we examine the future landscape of the Biotech sector, looking at the companies Defence Therapeutics, MorphoSys, BioNTech, and Pfizer. Infectious diseases are...
Defence-Therapeutics

Defence Therapeutics partners with pharmaceutical experts

Biotechnology company Defence Therapeutics has partnered with a pharmaceutical consultancy to maximise the potential of its developments. In a bid to strengthen its development of...
Collaboration formed to test efficacy of breast cancer therapy

Collaboration formed to test efficacy of breast cancer therapy

Defence Therapeutics Inc. has announced the establishment of a collaboration with the Curie Institute to evaluate the therapeutic efficacy of Accum-T-DM1 ADC in patient-derived...

Defence Therapeutics: Transforming drug delivery and improving treatment

Defence Therapeutics is continuously expanding on its portfolio of solutions to enhance drug delivery and improve treatment outcomes for patients with cancer and infectious...
Defence Therapeutics Accutox exhibits potent anti-cancer properties

Defence Therapeutics Accutox exhibits potent anti-cancer properties

Defence Therapeutics Inc. has announced a major breakthrough advance in its pre-clinical research program on its AccuTOX molecules as potent anti-cancer agents. The AccumTM technology...
Defence Therapeutics technology holds promise for future cancer therapy

Defence Therapeutics technology holds promise for future cancer therapy

Canadian biotechnology company Defence Therapeutics has developed a new generation platform technology that offers hope for future cancer therapy. Defence Therapeutics’ ACCUM™ technology can be...

Towards a cancer revolution with new targeted therapeutics

Defence Therapeutics Inc’s proprietary new platform offers a revolution in drug delivery. Quebec-based biotechnology developer Defence Therapeutics Inc specialises in antibody-drug conjugates (ADCs), a novel...
Defence therapeutics vaccine against cancer makes progress

Defence therapeutics vaccine against cancer makes progress

Defence Therapeutics has recently reported its first successes in the fight against cancer with a vaccine. Defence Therapeutics is a Canadian scientific pioneer, uncovering enhanced...
Collaboration established for the optimisation of cancer therapeutic

Collaboration established for the optimisation of cancer therapeutic

Defence Therapeutics Inc. has established a collaboration with the HUS Comprehensive Cancer Center at Helsinki, Finland, for the optimisation of Defence’s Accum-T-DM1 ADC Therapeutic. Defence...

Health Special Reports

Health eBooks

Health Partners

Pin It on Pinterest